Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells

• Published in: Blood Vol. 121; no. 20; pp. 4175 - 4183
• Main Authors: Bolton-Gillespie, Elisabeth, Schemionek, Mirle, Klein, Hans-Ulrich, Flis, Sylwia, Hoser, Grazyna, Lange, Thoralf, Nieborowska-Skorska, Margaret, Maier, Jacqueline, Kerstiens, Linda, Koptyra, Mateusz, Müller, Martin C., Modi, Hardik, Stoklosa, Tomasz, Seferynska, Ilona, Bhatia, Ravi, Holyoake, Tessa L., Koschmieder, Steffen, Skorski, Tomasz
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 16.05.2013; American Society of Hematology
• Subjects: Animals; Antineoplastic Agents - therapeutic use; Benzamides - therapeutic use; Cells, Cultured; DNA Damage - drug effects; Drug Resistance, Neoplasm - genetics; Genomic Instability - drug effects; Genomic Instability - physiology; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology; Mice; Mice, Transgenic; Myeloid Neoplasia; Neoplastic Stem Cells - drug effects; Neoplastic Stem Cells - metabolism; Neoplastic Stem Cells - pathology; Neoplastic Stem Cells - physiology; Oxidative Stress - drug effects; Oxidative Stress - genetics; Piperazines - therapeutic use; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Pyrimidines - therapeutic use; Reactive Oxygen Species - metabolism

Genomic instability is a hallmark of chronic myeloid leukemia in chronic phase (CML-CP) resulting in BCR-ABL1 mutations encoding resistance to tyrosine kinase inhibitors (TKIs) and/or additional chromosomal aberrations leading to disease relapse and/or malignant progression. TKI-naive and TKI-treate...